Pulmonx (NASDAQ:LUNG) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Pulmonx (NASDAQ:LUNG) from a sell rating to a hold rating in a research note released on Sunday morning.

LUNG has been the topic of several other reports. Piper Sandler lowered shares of Pulmonx from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $9.00 to $2.50 in a research note on Thursday, July 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a report on Wednesday, October 8th. Stifel Nicolaus lowered their price target on Pulmonx from $16.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 31st. Wells Fargo & Company cut their price objective on Pulmonx from $6.00 to $3.00 and set an “equal weight” rating for the company in a research report on Friday, August 1st. Finally, D. Boral Capital reiterated a “buy” rating and set a $14.00 target price on shares of Pulmonx in a research note on Thursday. Five investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $6.81.

Pulmonx Stock Down 4.7%

Shares of Pulmonx stock traded down $0.07 on Friday, reaching $1.42. 633,315 shares of the company were exchanged, compared to its average volume of 1,019,976. The company has a market capitalization of $58.58 million, a price-to-earnings ratio of -1.01 and a beta of 0.44. The company has a current ratio of 4.86, a quick ratio of 4.15 and a debt-to-equity ratio of 0.62. Pulmonx has a one year low of $1.37 and a one year high of $9.37. The company has a 50-day moving average of $1.71 and a 200 day moving average of $2.33.

Pulmonx (NASDAQ:LUNG) last released its earnings results on Wednesday, November 12th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06. The business had revenue of $21.50 million during the quarter, compared to analysts’ expectations of $20.78 million. Pulmonx had a negative net margin of 61.91% and a negative return on equity of 77.58%. Pulmonx has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Pulmonx will post -1.55 earnings per share for the current year.

Institutional Investors Weigh In On Pulmonx

Several hedge funds have recently bought and sold shares of the stock. Corton Capital Inc. acquired a new position in shares of Pulmonx in the second quarter valued at approximately $32,000. R Squared Ltd bought a new stake in Pulmonx in the 2nd quarter valued at $41,000. Bank of Montreal Can acquired a new position in Pulmonx in the 2nd quarter valued at $53,000. Perkins Capital Management Inc. grew its holdings in Pulmonx by 110.0% in the 3rd quarter. Perkins Capital Management Inc. now owns 21,000 shares of the company’s stock valued at $34,000 after buying an additional 11,000 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in Pulmonx by 95.8% during the 3rd quarter. SG Americas Securities LLC now owns 24,863 shares of the company’s stock worth $40,000 after buying an additional 12,166 shares during the period. 91.04% of the stock is currently owned by institutional investors and hedge funds.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.